Assessment of Cancer-related Post-traumatic Stress in Patients and Caregivers in the Year Following Diagnosis, and Identification of Their Expectations of Personalized Support - CANDYSTRESS (CANDYSTRESS)

April 23, 2025 updated by: Lille University

Évaluation de la détresse Post-traumatique Relative au Cancer Dans l'année Suivant le Diagnostic Chez Les Patients et Les Aidants et Identification de Leurs Attentes Envers un Accompagnement personnalisé

The impact of cancer on the lives of patients and their caregivers is undeniable. In addition to the potentially traumatic aspects (i.e., creating a very violent emotional shock) linked to the announcement of the disease and the various stages of the care pathway (effects of treatment, announcement of a cancer recurrence), even before the onset of the disease, patients and their caregivers may have been directly or indirectly confronted with traumatogenic events (e.g., childhood abuse, sudden death). They may therefore be more likely to develop a stress-related mental disorder in their lifetime. The question of the accumulation of traumatic events, the identification of groups of people at risk of developing symptoms of distress, and the management of these symptoms is therefore crucial. In addition, the mutual influence within the patient-caregiver dyad in terms of emotional adjustment, and its evolution throughout the cancer care pathway, are key elements to be considered in these issues.

The CandyStress project is based on a partnership with patients, their caregivers and carers to identify the needs of patient-caregiver dyads at risk of cancer-related post-traumatic stress disorder (Ca-PTS). Longitudinal screening for Ca-PTS in the year following cancer diagnosis will be carried out to identify the characteristics of at-risk dyads who could benefit from long-term support. The aim of this project is to identify the potential need for targeted support and the desired format of this support. This is a preliminary step in identifying needs and the context conducive to the implementation of personalized support, but in no way an evaluation of the effectiveness of an intervention.

Study Overview

Study Type

Observational

Enrollment (Estimated)

350

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Nord
      • Lille, Nord, France, 59000
      • Lille, Nord, France, 5900
        • Recruiting
        • Centre Oscar Lambret
        • Contact:
          • Nicolas PENEL, MD, PhD
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

centre oscar lambret

Description

Inclusion Criteria:

Part 1. Diagnosis of Ca-PTS

Patient inclusion criteria:

  • Male or female, 18 years of age or older,
  • recently (<4 months) diagnosed with breast, gynecological, testicular or digestive cancer at the time of the announcement visit (i.e., the announcement to the patient of the treatment plan after the initial multidisciplinary consultation meeting in the cancer center - in accordance with the Cancer Plan),
  • with cancer requiring oncological treatment,
  • starting oncology treatment at the Oscar Lambret Center,
  • with no Central Nervous System (CNS) metastases,
  • with a PRONOPALL score ≤3 (favorable prognosis group, Bourgeois et al., 2017) or expected survival greater than 6 months,
  • who have given signed consent to participate in the study and are covered by French social security,
  • able to identify a caregiver (i.e., a family member, friend or other person who has helped care for them since diagnosis).
  • equipped with a computer or tablet equipped with a webcam and an internet connection, for the online questionnaire - the webcam is only necessary if the participant wants the IGE to be present via video on the computer, if they prefer the video to be made over the phone, in which case they must also be equipped with a smartphone enabling video calls.

Inclusion criteria for caregivers:

  • Male or female, 18 years of age or older,
  • designated by the patient as their primary caregiver (i.e. "a family member, friend or other person who has helped care for you since diagnosis"),
  • have given their signed consent to participate in the study.
  • equipped with a computer or tablet equipped with a webcam and an internet connection, for the online questionnaire - the webcam is only necessary if the participant wishes the IGE to be present via video on the computer, if he/she prefers the video to be made over the phone, in which case it is also necessary to be equipped with a smartphone enabling video calls.

Part 2. Gathering expectations for personalized support and its components.

In addition, 3 types of focus groups will be set up remote :

Focus groups with patients from local associations, as well as patient partners of the Oscar Lambret Center and patients from Part 1 if they are interested.

Inclusion criteria for patient focus groups:

  • Men or women of legal age who have or have had cancer,
  • Members of a local patient association or of the Oscar Lambret Center's "patient partners" committee,
  • Or have participated in part 1 (Ca-PTS screening, once the 3 steps have been completed),
  • Equipped with a computer or tablet with camera and internet connection,
  • Have given their consent to take part in the study.

Focus group with caregivers from local associations as well as "partner caregivers" from the Oscar Lambret Center and caregivers from part 1 if they are interested.

Inclusion criteria for "caregiver" focus groups:

  • Men or women of full age who are, or have been, caregivers of a cancer patient,
  • members of a local caregivers' association,
  • or having participated in part 1 (Ca-PTS screening, once the 3 steps have been completed),
  • Equipped with a computer or tablet with camera and internet connection,
  • Having given their consent to take part in the study.

Focus groups with hospital medical and paramedical staff as well as non-hospital caregivers involved in the medical in the medical and psychological follow-up of patients.

Inclusion criteria for caregiver focus groups:

  • Member of the medical and paramedical staff of the Oscar Lambret Center
  • Or non-hospital staff involved in the medical or psychological care of patients,
  • Professionals not involved in the present study,
  • Equipped with a computer or tablet with camera and internet connection
  • Having given their consent to participate in the study

Exclusion Criteria:

Part 1. Diagnosis of Ca-PTS

Non inclusion criteria for patients :

  • Patients with meningeal or cerebral metastases,
  • Patients with cancer recurrence,
  • Patients suffering from a psychiatric or neurological disorder likely to impair their ability to reason or judge (in particular psychotic disorder, autism spectrum disorder, intellectual disability),
  • Patients with a psychological or physical incapacity to answer questionnaires, certified by medical staff,
  • Patients subject to a custodial sentence, guardianship or protection of vulnerable adults,
  • Presence of CNS metastases (risk of cognitive impairment preventing completion of questionnaires).

Non-inclusion criteria for caregivers:

  • Caregivers suffering from a psychiatric or neurological disorder likely to impair their ability to reason or exercise judgment judgment (in particular psychotic disorder, autism spectrum disorder intellectual disability), or for whom there is a suspicion (not there is a suspicion (no additional examination is prescribed to confirm this criterion, which remains self-declaratory).
  • Caregivers with a psychological or physical inability to answer questionnaires, or for whom there is a suspicion suspicion (no further tests are required to confirm this criterion which remains self-reported).
  • Caregivers subject to a custodial sentence, guardianship or protection guardianship or protection of vulnerable adults.

Part 2. Collection of expectations for personalized support and its components.

Non-inclusion criteria for patients and caregivers who participated in the screening part of the Ca-PTS :

- Failure to complete all measurement times (T0, T1, T2)

Non-inclusion criteria for focus groups (patients, caregivers): none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Part 1 - patients groups
(n = 150) = Male or female, 18 years of age or older, recently (<4 months) diagnosed with breast, gynecological, testicular or digestive cancer at the time of the announcement visit (i.e., the announcement to the patient of the treatment plan after the initial multidisciplinary consultation meeting in the cancer center)
Part 1 - caregivers group
(n = 150) = Men or women aged 18 or over, designated by the patient as their primary caregiver (i.e. "a family member, friend or other person who has helped care for you since your diagnosis")
Part 2 - patients

Men or women of legal age who have or have had cancer, Members of a local patient association or of the Oscar Lambret Center's "patient partners" committee.

For each type of participant (patients, caregivers, healthcare professionals), 3 focus groups will be set up to collect a sufficient amount of data to reach data saturation (Guest et al., 2017; Wilkinson, 2013). In all, 9 focus groups will be set up. Each group will have between 4 and 8 participants.

Part 2 - caregivers

Men or women of legal age who are or have been caregivers for a cancer patient, members of a local caregivers' association.

For each type of participant (patients, caregivers, healthcare professionals), 3 focus groups will be set up to collect a sufficient amount of data to reach data saturation (Guest et al., 2017; Wilkinson, 2013). In all, 9 focus groups will be set up. Each group will have between 4 and 8 participants.

Part 2 - healthcare professionals

Medical and paramedical staff at the Oscar Lambret Center Or non-hospital personnel involved in the medical or psychological care of patients, Professionals not involved in the present study.

For each type of participant (patients, caregivers, healthcare professionals), 3 focus groups will be set up to collect a sufficient amount of data to reach data saturation (Guest et al., 2017; Wilkinson, 2013). In all, 9 focus groups will be set up. Each group will have between 4 and 8 participants.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PTSD Checklist for DSM-5 (PCL5)
Time Frame: measured in the month following the announcement of the cancer treatment, then 6 months and 12 months later - in patients and their caregiver
total score (0-80) reflects the severity of Post Traumatic Stress Disorder (PTSD) symptoms. A score threshold > 32 has been validated as reflecting probable PTSD
measured in the month following the announcement of the cancer treatment, then 6 months and 12 months later - in patients and their caregiver

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
self reported general physical condition
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
answer to the item "How do you feel physically impaired at the moment?" (likert scale from 0: "not at all" to 10: "absolutely")
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
perception of the general physical condition in the other dyad member
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
answer to the item:: "To what extent do you think your loved one feels physically diminished at the moment? " (likert scale from 0: "not at all" to 10: "absolutely")
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
self reported distress
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
answer to the item "To what extent do you feel psychologically distressed at the moment? " ((likert scale from 0: "not at all" to 10: "absolutely")
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
perception of the distress in the other dyad member
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
answer to the item: "To what extent do you think your loved one feels psychologically distressed at the moment? " (likert scale from 0: "not at all" to 10: "absolutely")
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
self reported physical pain (only in patients)
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
answer to the item "to what extent are you currently experiencing physical pain?" (likert scale from 0: "not at all" to 10: "absolutely")
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
exposure to potentially traumatic events
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
self reported Life Event Checklist for DSM-5 (LEC-5). The total score is 0 to 48. The higher the score, the more the participant reports traumatic events.
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
post traumatic stress disorder (PTSD)
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
PTSD checklist for DSM 5 (PCL-5). The total score (0-80) reflects the severity of the PSTD symptoms, and a cut off of 32 a possible PTSD.
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
anxiety symptoms
Time Frame: : from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Generalized Anxiety Disorder (GAD7). The overall score ranges from 0 to 21. Scores of 5, 10 and 15 represent thresholds for mild, moderate and severe anxiety respectively
: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
depressive symptoms
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Patient Health Questionnaire (PHQ9). The total score ranges from 0 to 27, with a score of 10 or more indicating moderate depression.
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
social support
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Social Support Questionnaire SSQ6. Higher SSQ6 scores reflect greater satisfaction with the level of social support.
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
difficulties in emotion regulation
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Difficulties in Emotion Regulation Scale Short Form (DERS SF). The higher the score, the greater the difficulty of emotional regulation.
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
resilience
Time Frame: from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Resilience Resources Scale (RSS). The total score ranges from 12 to 60. Higher scores reflect greater resilience
from baseline (in the month following the announcement of the cancer treatment) to 6 months and 12 months later
Questions about potential personalized support
Time Frame: baseline
Participants will be asked whether they personally feel the need for psychological support to manage their symptoms, and whether they would be willing to engage in such support. If so, they will be asked to specify when they think this support should be offered, and in what form These answers will be collected using open-ended questions.
baseline
Socio-demographic factors
Time Frame: at inclusion (i.e in the month following the announcement of the cancer treatment) - for patients and caregivers
age, gender, marital status, socio-professional category, level of education
at inclusion (i.e in the month following the announcement of the cancer treatment) - for patients and caregivers

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 2, 2025

Primary Completion (Estimated)

February 5, 2027

Study Completion (Estimated)

February 2, 2028

Study Registration Dates

First Submitted

April 3, 2025

First Submitted That Met QC Criteria

April 23, 2025

First Posted (Actual)

April 25, 2025

Study Record Updates

Last Update Posted (Actual)

April 25, 2025

Last Update Submitted That Met QC Criteria

April 23, 2025

Last Verified

April 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cancer

Subscribe